The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RCKT | -50.95% | -91.59% | -39.01% | -65% |
| S&P | +17.45% | +75.43% | +11.88% | +146% |
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Its near-term risks are subtle but bigger than their flying stock price might indicate.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$2,217.00K | 6.1% |
| Market Cap | $379.86M | -71.6% |
| Market Cap / Employee | $1.88M | 0.0% |
| Employees | 202 | -32.4% |
| Net Income | -$42,538.00K | 29.5% |
| EBITDA | -$41,814.00K | 30.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $77.56M | -52.6% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.96M | -3.0% |
| Short Term Debt | $2.92M | 2.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -52.00% | -4.7% |
| Return On Invested Capital | -41.02% | -6.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34,922.00K | 26.1% |
| Operating Free Cash Flow | -$34,842.00K | 25.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.53 | 0.63 | 0.99 | 1.21 | -65.13% |
| Price to Tangible Book Value | 1.78 | 0.75 | 1.21 | 1.52 | -64.70% |
| Enterprise Value to EBITDA | -7.19 | -0.39 | -3.38 | -5.46 | -62.53% |
| Return on Equity | -60.5% | -69.6% | -74.9% | -60.3% | 11.31% |
| Total Debt | $25.35M | $25.20M | $25.05M | $24.88M | -2.44% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
